Bengaluru-based biotech startup StrainX Biotech has raised $13 million in its latest funding round, marking a significant step in its mission to advance strain engineering, protein engineering, and industrial biotechnology applications.
The round saw participation from investors including Prime Venture Partners, Leo Capital, Sunicon Ventures, Dholakia Ventures, and WindT Angels. The company plans to deploy the fresh capital to strengthen research and development, expand fermentation production capacity, hire additional scientists and engineers, and accelerate global commercialization of its biotech solutions.
Founded by Akshay Mittal and Alok Malviya, StrainX Biotech focuses on developing genetically optimized microbial strains and biological systems designed to improve yield efficiency and reduce production costs across life sciences and pharmaceutical manufacturing.
The company operates as a B2B deep-tech platform in synthetic biology, targeting sectors such as precision fermentation, biomanufacturing, and custom protein design. It aims to position itself among emerging global players in the biotech space while leveraging India’s scientific talent and cost advantages.
According to the founders, investor interest was driven by the scalability of the technology and the relatively early positioning of the company within India’s growing biotech ecosystem. The startup also highlights that only a small number of global companies are currently working in similar areas, creating strong long-term market potential.
With this funding round, StrainX Biotech plans to expand its operational footprint and accelerate its path toward becoming a global player in next-generation bio-manufacturing technologies.
